Developer docs
API playgroundTry for free, no card

Search company profiles

Integral BioSystems

Full company profile

uuid000jj38

Namestring
Integral BioSystems
Legal namestring
Integral BioSystems, LLC
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Integral BioSystems, LLC is a privately held contract research organization (CRO) founded in 2009 and fully operational since 2011, headquartered in Bedford, Massachusetts. The company provides specialty drug formulation development services for bio-pharmaceutical clients across multiple delivery routes including ophthalmic, injectable, dermal, otic, pulmonary, intranasal, oral, sublingual, and rectal dosage forms. Service offerings include formulation development, analytical method development, cGLP toxicology supply generation, and scale-up/technology transfer, executed from a ~10,000 sq ft cGLP-compliant laboratory facility.

The company's technology portfolio centers on proprietary drug delivery platforms designed to overcome bioavailability and sustained-release challenges. These include the OcuHeal™ Lipid Nanoparticle (LNP) platform using liquid-crystalline nanolipid structures with membrane-interactive permeation enhancers; the NanoM Wafer™ Ocular Insert technology with dissolvable and non-dissolvable thin-film variants; the OcuSurf™ Nanocore Delivery System for biphasic nano-dispersions; and the EySite Platform for PLGA microspheres with sub-0.5% burst release. These platforms are patented across 12-14 global jurisdictions and positioned for 505(b)(2) product development pathways.

Integral BioSystems operates a dual business model combining fee-for-service CRO engagements with out-licensing of proprietary delivery platforms. Revenue is generated through project-based CRO contracts (quote-based pricing by scope, molecule, and stage) and technology licensing collaborations. The company is owned by founders Dr. Shikha Barman (CEO/CTO) and Dave Karasic (COO/Legal/IP). In July 2022, the company established Symphony Therapeutics as a wholly-owned subsidiary to advance platform product commercialization, including OcuHeal-UV400+ (UV/blue-light protective eyedrop) and the NanoM-Wafer™ Artificial Tear Film Ocular Insert (dry-eye treatment), with Europe targeted as the initial proprietary-product market.

Short descriptiontext

Integral BioSystems is a Bedford, Massachusetts-based pharmaceutical contract research organization founded in 2009, providing specialty formulation development and cGLP services across ophthalmic, injectable, and other delivery routes, while licensing proprietary OcuHeal™ LNP and NanoM Wafer™ drug delivery platforms to bio-pharmaceutical clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBedford, United States
HQ citystring
Bedford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery formulation, contract research services, ophthalmic drug delivery, nanoparticle therapeutics, pharmaceutical R&D services
Industry2 codes
PRIMARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in Nanotechnology541713
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Research & Drug Delivery Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CRO Fee-for-Service Contracts
TypeProfessional Services
Description

Contract research organization services including formulation development, analytical method development, cGLP toxicology supply generation, and scale-up/technology transfer. Services billed on project basis with pricing quote-based.

integralbiosystems.com
2Technology Licensing
TypeLicensing Royalties
Description

Out-licensing of proprietary delivery platforms (OcuHeal™ LNP and NanoM Wafer™) to pharmaceutical companies for 505(b)(2) product development. Company seeks licensing collaborations for additional applications in ophthalmology, urology, and intranasal routes.

integralbiosystems.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1OcuHeal
Description

Lipid nanoparticle (LNP) platform technology for ocular, otic, intranasal, and dermal drug delivery applications. The platform is patented globally and used for 505(b)(2) products.

integralbiosystems.com
+3 more records
Core offering1 text field

Integral BioSystems is a contract research organization that provides drug delivery and formulation development services for ocular, dermatologic, and nano-medicine applications. The company develops and licenses proprietary drug delivery platforms including OcuHeal™ LNP, NanoM Wafer™, OcuSurf™, and EySite for sustained, targeted, and nanoparticle-based delivery of small molecules and biologics. Through its subsidiary Symphony Therapeutics, it advances clinical-stage ophthalmic assets for pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Free base formulation delivered ~80% more total drug recovered from corneal tissue compared to hydrochloride salt (88.8 μg vs 49.0 μg)
+2 more records
Product overview1 text field

Integral BioSystems operates as a pharmaceutical contract research organization (CRO) offering a hybrid model of fee-for-service CRO work and proprietary, licensable drug delivery platforms. The core product portfolio includes two main platform technologies: the OcuHeal™ LNP (Lipid Nanoparticle) Platform and the NanoM Wafer™ Sustained-Release Ocular Insert Platform, both of which are patented globally and available for licensing. The OcuSurf™ Nanocore Delivery System represents an earlier iteration of the lipid nanoparticle technology for ophthalmic formulations. The EySite Platform provides PLGA microsphere-based sustained delivery for the posterior segment. Under the wholly-owned subsidiary Symphony Therapeutics (founded July 2022), the company advances product-specific applications including OcuHeal-UV400+ (UV-protective eyedrop) and the NanoM-Wafer™ Artificial Tear Film Ocular Insert for dry eye treatment. CRO services span formulation development, analytical method development, and scale-up across multiple delivery routes including ophthalmic, injectable, dermal, and pulmonary applications.

Product and service6 records
1OcuHeal™ LNP
CategoryDrug Delivery Platform
Description

Proprietary lipid nanoparticle-based ocular drug delivery platform for sustained and targeted delivery of small molecules and biologics to the eye. Targeted at bio-pharmaceutical partners developing ophthalmic therapeutics.

2NanoM Wafer™
CategoryDrug Delivery Platform
Description

Proprietary nano-medicine wafer-based delivery platform for sustained release drug delivery applications. Targeted at pharmaceutical developers requiring controlled-release formulations.

3OcuSurf™
CategoryDrug Delivery Platform
Description

Proprietary ocular drug delivery platform for topical/surface-based ophthalmic delivery of therapeutics. Targeted at bio-pharmaceutical partners developing eye drop and surface-acting ophthalmic products.

4EySite
CategoryDrug Delivery Platform
Description

Proprietary ophthalmic drug delivery platform supporting site-specific ocular therapeutics delivery. Targeted at bio-pharmaceutical developers of targeted ophthalmic drugs.

5Drug Delivery Formulation CRO Services
CategoryContract Research Services
Description

Contract research services encompassing formulation development, analytical method development, and characterization for ocular, dermatologic, and nano-medicine drug delivery programs. Targeted at bio-pharmaceutical R&D teams.

6Symphony Therapeutics (Subsidiary) Clinical Development
CategoryClinical Development Services
Description

Clinical-stage ophthalmic development arm operating as a subsidiary, advancing ophthalmic therapeutic assets derived from Integral BioSystems' delivery platforms. Targeted at pharmaceutical partners seeking clinical-translational ophthalmic development.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Symphony Therapeutics
Strategic tierCoreTypeOthersAnnounced on2026-03-01
Description

Wholly-owned subsidiary founded July 2022, used to advance platform products including OcuHeal™ and NanoM Wafer™. Symphony Therapeutics conducts investor outreach and identifies development partners for delivery platforms. Initial market introduction targeted for Europe.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Collaboration and license deal for NanoM™ technology. Nacuity Pharmaceuticals licensed Integral BioSystems' NanoM™ drug formulation technology for development of ophthalmic products.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers17 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Integral BioSystems

Pharmaceutical Contract Research & Drug Delivery Servicesintegralbiosystems.com

Integral BioSystems is a Bedford, Massachusetts-based pharmaceutical contract research organization founded in 2009, providing specialty formulation development and cGLP services across ophthalmic, injectable, and other delivery routes, while licensing proprietary OcuHeal™ LNP and NanoM Wafer™ drug delivery platforms to bio-pharmaceutical clients.

What Integral BioSystems does

Integral BioSystems, LLC is a privately held contract research organization (CRO) founded in 2009 and fully operational since 2011, headquartered in Bedford, Massachusetts. The company provides specialty drug formulation development services for bio-pharmaceutical clients across multiple delivery routes including ophthalmic, injectable, dermal, otic, pulmonary, intranasal, oral, sublingual, and rectal dosage forms. Service offerings include formulation development, analytical method development, cGLP toxicology supply generation, and scale-up/technology transfer, executed from a ~10,000 sq ft cGLP-compliant laboratory facility.

The company's technology portfolio centers on proprietary drug delivery platforms designed to overcome bioavailability and sustained-release challenges. These include the OcuHeal™ Lipid Nanoparticle (LNP) platform using liquid-crystalline nanolipid structures with membrane-interactive permeation enhancers; the NanoM Wafer™ Ocular Insert technology with dissolvable and non-dissolvable thin-film variants; the OcuSurf™ Nanocore Delivery System for biphasic nano-dispersions; and the EySite Platform for PLGA microspheres with sub-0.5% burst release. These platforms are patented across 12-14 global jurisdictions and positioned for 505(b)(2) product development pathways.

Integral BioSystems operates a dual business model combining fee-for-service CRO engagements with out-licensing of proprietary delivery platforms. Revenue is generated through project-based CRO contracts (quote-based pricing by scope, molecule, and stage) and technology licensing collaborations. The company is owned by founders Dr. Shikha Barman (CEO/CTO) and Dave Karasic (COO/Legal/IP). In July 2022, the company established Symphony Therapeutics as a wholly-owned subsidiary to advance platform product commercialization, including OcuHeal-UV400+ (UV/blue-light protective eyedrop) and the NanoM-Wafer™ Artificial Tear Film Ocular Insert (dry-eye treatment), with Europe targeted as the initial proprietary-product market.

Integral BioSystems firmographics

Firmographics
Name
Integral BioSystems
Legal name
Integral BioSystems, LLC
Website
https://integralbiosystems.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Integral BioSystems is a Bedford, Massachusetts-based pharmaceutical contract research organization founded in 2009, providing specialty formulation development and cGLP services across ophthalmic, injectable, and other delivery routes, while licensing proprietary OcuHeal™ LNP and NanoM Wafer™ drug delivery platforms to bio-pharmaceutical clients.
Ownership category
akta.pro rank

Integral BioSystems industry classification

Industry
Product category
Pharmaceutical Contract Research & Drug Delivery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Drug delivery formulation
  • Contract research services
  • Ophthalmic drug delivery
  • Nanoparticle therapeutics
  • Pharmaceutical R&D services

Where Integral BioSystems is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Integral BioSystems business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CRO Fee-for-Service Contracts: Contract research organization services including formulation development, analytical method development, cGLP toxicology supply generation, and scale-up/technology transfer. Services billed on project basis with pricing quote-based.
  2. Technology Licensing: Out-licensing of proprietary delivery platforms (OcuHeal™ LNP and NanoM Wafer™) to pharmaceutical companies for 505(b)(2) product development. Company seeks licensing collaborations for additional applications in ophthalmology, urology, and intranasal routes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Integral BioSystems product offering

Product offering

Core offering

Integral BioSystems is a contract research organization that provides drug delivery and formulation development services for ocular, dermatologic, and nano-medicine applications. The company develops and licenses proprietary drug delivery platforms including OcuHeal™ LNP, NanoM Wafer™, OcuSurf™, and EySite for sustained, targeted, and nanoparticle-based delivery of small molecules and biologics. Through its subsidiary Symphony Therapeutics, it advances clinical-stage ophthalmic assets for pharmaceutical partners.

Product overview

Integral BioSystems operates as a pharmaceutical contract research organization (CRO) offering a hybrid model of fee-for-service CRO work and proprietary, licensable drug delivery platforms. The core product portfolio includes two main platform technologies: the OcuHeal™ LNP (Lipid Nanoparticle) Platform and the NanoM Wafer™ Sustained-Release Ocular Insert Platform, both of which are patented globally and available for licensing. The OcuSurf™ Nanocore Delivery System represents an earlier iteration of the lipid nanoparticle technology for ophthalmic formulations. The EySite Platform provides PLGA microsphere-based sustained delivery for the posterior segment. Under the wholly-owned subsidiary Symphony Therapeutics (founded July 2022), the company advances product-specific applications including OcuHeal-UV400+ (UV-protective eyedrop) and the NanoM-Wafer™ Artificial Tear Film Ocular Insert for dry eye treatment. CRO services span formulation development, analytical method development, and scale-up across multiple delivery routes including ophthalmic, injectable, dermal, and pulmonary applications.

Differentiator

Problem solved

Functional benefit

Brands

  • OcuHeal: Lipid nanoparticle (LNP) platform technology for ocular, otic, intranasal, and dermal drug delivery applications. The platform is patented globally and used for 505(b)(2) products.
  • NanoM Wafer
  • OcuSurf
  • EySite

Products and services

  • OcuHeal™ LNP Proprietary lipid nanoparticle-based ocular drug delivery platform for sustained and targeted delivery of small molecules and biologics to the eye. Targeted at bio-pharmaceutical partners developing ophthalmic therapeutics.
  • NanoM Wafer™ Proprietary nano-medicine wafer-based delivery platform for sustained release drug delivery applications. Targeted at pharmaceutical developers requiring controlled-release formulations.
  • OcuSurf™ Proprietary ocular drug delivery platform for topical/surface-based ophthalmic delivery of therapeutics. Targeted at bio-pharmaceutical partners developing eye drop and surface-acting ophthalmic products.
  • EySite Proprietary ophthalmic drug delivery platform supporting site-specific ocular therapeutics delivery. Targeted at bio-pharmaceutical developers of targeted ophthalmic drugs.
  • Drug Delivery Formulation CRO Services Contract research services encompassing formulation development, analytical method development, and characterization for ocular, dermatologic, and nano-medicine drug delivery programs. Targeted at bio-pharmaceutical R&D teams.
  • Symphony Therapeutics (Subsidiary) Clinical Development Clinical-stage ophthalmic development arm operating as a subsidiary, advancing ophthalmic therapeutic assets derived from Integral BioSystems' delivery platforms. Targeted at pharmaceutical partners seeking clinical-translational ophthalmic development.

Quantifiable outcome

  • Free base formulation delivered ~80% more total drug recovered from corneal tissue compared to hydrochloride salt (88.8 μg vs 49.0 μg)
  • +2 more outcomes

Companies that use Integral BioSystems

Customer profile

Named customers17 records

Segments3 records

Ideal customer profiles1 record

Integral BioSystems technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Integral BioSystems partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Symphony TherapeuticscoreOthers · 1 March 2026Wholly-owned subsidiary founded July 2022, used to advance platform products including OcuHeal™ and NanoM Wafer™. Symphony Therapeutics conducts investor outreach and identifies development partners for delivery platforms. Initial market introduction targeted for Europe.
  • Nacuity PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2023Collaboration and license deal for NanoM™ technology. Nacuity Pharmaceuticals licensed Integral BioSystems' NanoM™ drug formulation technology for development of ophthalmic products.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Integral BioSystems competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights7 records

Customer concentration

Integral BioSystems social profiles

Digital presence

Integral BioSystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Integral BioSystems leadership team

Management profile

Number of profiles

Profiles2 records

Integral BioSystems subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Integral BioSystems funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Integral BioSystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integral BioSystems

What does Integral BioSystems do?

Integral BioSystems is a contract research organization that provides drug delivery and formulation development services for ocular, dermatologic, and nano-medicine applications. The company develops and licenses proprietary drug delivery platforms including OcuHeal™ LNP, NanoM Wafer™, OcuSurf™, and EySite for sustained, targeted, and nanoparticle-based delivery of small molecules and biologics. Through its subsidiary Symphony Therapeutics, it advances clinical-stage ophthalmic assets for pharmaceutical partners.

Is Integral BioSystems a public or private company?

Integral BioSystems is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Integral BioSystems founded?

Integral BioSystems was founded in 2009. It employs 11 to 50 people.

Where is Integral BioSystems based?

Integral BioSystems is headquartered in Bedford, United States, in the North America region.

How does Integral BioSystems make money?

Two revenue lines are on record. CRO Fee-for-Service Contracts are the primary driver. The others are technology Licensing.

Does Integral BioSystems have an API?

No public API is recorded for Integral BioSystems.

What industry is Integral BioSystems in?

Integral BioSystems's product category is Pharmaceutical Contract Research & Drug Delivery Services. Its primary akta.pro industry code is HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireIntegral BioSystems Announces Next Steps for its Flagship Products based on OcuHeal and NanoM-Wafer PlatformsIntegral BioSystems is seeking seed round financing for its NanoM-Wafer Lubricating Bandage and OcuHeal-UV400+ ophthalmic products through Symphony Therapeutics. The NanoM-Wafer treats dry eye via a hydrogel bandage, while OcuHeal-UV400+ is a UV-blocking antioxidant eyedrop. Both are patented in 14 jurisdictions and planned for initial European launch.EIN PresswireIntegral BioSystems Files Additional Extensive NanoM-Wafer™ PCTs in Major Global Jurisdictions to Secure Evolving IPIntegral BioSystems filed additional PCTs for its NanoM-Wafer dry-eye bandage in major jurisdictions. The device transforms into a hydrogel lasting 11-13 hours and is being licensed to spin-off Symphony Therapeutics. The company plans first-in-human studies and initial European launch.EIN PresswireIntegral BioSystems Attending Drug Development Contracting & Outsourcing Conference Sept 24, 2026 in New Brunswick NJIntegral BioSystems will exhibit at Table #41 at the Drug Development Contracting & Outsourcing Conference on Sept 24, 2026, in New Brunswick, NJ. The company offers formulation development for small and large molecules, including biodegradable microspheres, drug suspensions, and vaccines, with delivery routes such as injectables and ophthalmics.EIN PresswireCall to Entrepreneurs and Start-ups! Integral BioSystems Offers Rapid Testing ServicesIntegral BioSystems, a drug delivery CRO, is offering fast-track testing packages to startups and fledgling companies to rapidly develop analytical methods and formulations for preclinical assurance. The company provides turn-key services including particle sizing, stability testing, and cGLP, and invites early-stage projects for discussion.EIN PresswireIntegral BioSystems to Present on the NanoM-Wafer Technology at ARVO 2026Integral BioSystems will present its NanoM-Wafer ocular insert technology at ARVO 2026 in Denver, Colorado, on May 5, 2026. The company reports 7-day sustained release of intact proteins and linear release of an anti-inflammatory drug. It invites ophthalmic drug developers to collaborate.EIN PresswireIntegral BioSystems to Present on the NanoM-Wafer Technology at ARVO 2026Integral BioSystems will present its NanoM-Wafer technology at ARVO 2026 in Denver, Colorado, on May 5, 2026. The company's OcuHeal-UV400+ product, based on lipid nanoparticle technology, blocks UV-A, UV-B, and blue light, and is designed for corneal surface disorders. The presentation is a poster session on once-weekly medication administration.EIN PresswireIntegral BioSystems to Present on OcuHeal-UV400+, an UV-Protective LNP EyedropIntegral BioSystems will present data on OcuHeal-UV400+, a UV-blocking antioxidant eyedrop, at the ARVO convention in Denver on May 5, 2026. The product uses a lipid nanoparticle platform with a GRAS plant-based compound that blocks UV-A, UV-B, and blue light, and is biocompatible with corneal epithelial cells.EIN PresswireIntegral BioSystems to Present NanoM-Wafer™ Artificial Tear Film Ocular Insert at ARVO 2026 in DenverIntegral BioSystems will present data on its NanoM-Wafer artificial tear film ocular insert at ARVO 2026 in Denver. The 200-micron wafer hydrates and forms a tissue-interlocking hydrogel to treat dry eye, with prototypes tested in rabbit models. The product is being developed as a medical device for initial European introduction.EIN PresswireSymphony Therapeutics to Present NanoM-Wafer™ Artificial Tear Film Ocular InsertSymphony Therapeutics, a wholly-owned subsidiary of Integral BioSystems based in Bedford, MA, will present data on its NanoM-Wafer™ Artificial Tear Film Ocular Insert at the 2026 TechConnect World Innovation Conference and Expo on March 11, 2026 in Raleigh, NC. The insert is a 200-micron dry wafer that hydrates into a transparent, tissue-interlocking hydrogel when placed under the lower eyelid to treat dry eye symptoms, representing a next-generation advancement over the existing Lacrisert product. The company, which holds patents in 14 global jurisdictions, plans investor outreach to identify development partners for both the NanoM-Wafer and OcuHeal™ drug delivery platforms, with initial market introduction targeted for Europe.PR NewswireSpecialty Drug Delivery Firm Integral BioSystems LLC to Exhibit at 2016 ARVO Annual Meeting in Seattle Washington May 1-4, 2016Integral BioSystems LLC, a Boston-area specialty drug delivery contract research organization focused on ophthalmological pharmaceutical formulation development, announced it will exhibit at the ARVO 2016 Annual Meeting in Seattle from May 1-4, 2016, where its CEO Dr. Shikha P. Barman will discuss the company's formulation development services with attendees.